1 Institut de Recherche pour le Développement (IRD)-PHPT, Chiang Mai University, Thailand.
2 Faculty of Associated Medical Sciences, Chiang Mai University, Thailand.
3 Department of Radiology and Biomedical Imaging, University of California-San Francisco.
4 Department of Radiology, Maharaj Nakorn Chiang Mai Hospital, Faculty of Medicine, Chiang Mai University, Thailand.
5 Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
6 Banglamung Hospital, Chon Buri.
7 Nopparat Rajathanee Hospital, Bangkok.
8 Samutprakarn Hospital, Samut Prakan.
9 Nakornping Hospital, Chiang Mai.
10 Khon Kaen Hospital, Thailand.
11 Chiang Kham Hospital, Thailand.
12 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, United Kingdom.
13 Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
14 Population Sciences in the Pacific Program, University of Hawaii Cancer Center, Honolulu.
15 Centers for Disease Control and Prevention, Atlanta, Georgia.
16 Department of HIV/Hepatitis, WHO Global Hepatitis Programme, Geneva, Switzerland.
17 Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland.
In a randomized, double-blind, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) use from 28 weeks gestational age to 2 months postpartum to prevent mother-to-child transmission of hepatitis B virus, there was no significant effect of maternal TDF use on maternal or infant bone mineral density 1 year after delivery/birth. Clinical Trials Registration. NCT01745822.